study question: Can the equilibration steps prior to embryo vitrification be automated? summary answer: We have developed the 'Gavi' system which automatically performs equilibration steps before closed system vitrification on up to four embryos at a time and gives in vitro outcomes equivalent to the manual Cryotop method.
Introduction
In the 35 years since the first human birth from in vitro fertilization (IVF), it is estimated that worldwide over 5 million babies have been conceived by assisted reproductive technologies (ART), half of which have been born in the last 6 years (Adamson et al., 2013) . During this time ART has seen substantial increases in success rates with skilled clinics achieving pregnancies in excess of 50% of embryo transfers (Cobo et al., 2010; Roy et al., 2014) . These improvements can be attributed to multiple developments including low oxygen benchtop incubators designed specifically for embryo culture, the use of sequential embryo media and culture to the blastocyst stage, intracytoplasmic sperm injection, and vitrification for oocyte and embryo cryopreservation (Jansen, 2005; Wang and Sauer, 2006; AbdelHafez et al., 2010; Bontekoe et al., 2012) . However, despite these advances IVF largely remains a manual timeconsuming and operator-dependent process and so far only one embryology procedure has been semi-automated: time-lapse monitoring of embryo morphokinetics (Meseguer et al., 2011 (Meseguer et al., , 2012 . As a consequence there is limited standardization of ART procedures and clinical outcomes vary greatly between IVF clinics and between embryologists.
The successful cryopreservation of supernumerary embryos is an essential practice during ART to maximize cumulative pregnancy rates, particularly for clinics performing single embryo transfers (Gerris, 2009) . The last decade has seen a shift from conventional slow-freezing towards vitrification due to superior recovery rates and clinical outcomes (Loutradi et al., 2008; AbdelHafez et al., 2010) . Vitrification is however one of the most time-consuming, manual and operator skill dependent procedures performed in an ART clinic (Gosden, 2011) , with some centres employing scientists solely dedicated to this task. Embryo vitrification typically employs the use of high concentrations of cryoprotectants followed by cryopreservation with liquid nitrogen to produce extremely rapid cooling rates (Kuwayama, 2007; Gosden, 2011) . This results in both the intracellular and extracellular solutions being rapidly solidified into a glasslike (vitreous) state which avoids detrimental ice crystal formation.
There are many vitrification devices and protocols available on the market today, which vary greatly in the constitution, exposure time and temperature of cryoprotectants, as well as in the volume of vitrification solution surrounding the embryo, the speed of cooling and warming rates, and whether or not the embryo comes in direct contact with liquid nitrogen (Kader et al., 2009; Alpha Scientists In Reproductive Medicine, 2012) . The gold standard of vitrification is arguably the Cryotop method, a room temperature vitrification system that has been used extensively and offers extremely high cooling and warming rates, reported to be 23 0008C/min and 42 0008C/min respectively (Kuwayama et al., 2005b; Kuwayama, 2007) . This system has been shown to produce embryo survival rates following cryopreservation of .90% and implantation, live birth rates and neonatal outcomes equivalent to those of fresh transfers (Takahashi et al., 2005; Kato et al., 2012; Roy et al., 2014) . One of the limitations of the standard Cryotop system as well as many other available devices is that the embryo comes in direct contact with liquid nitrogen, potentially exposing it to pathogens, and for this reason closed aseptic systems are preferred by many ART clinics (Bielanski, 2012) and is a regulatory directive of the European Union (European Union, 2004) .
To address the need for standardization of vitrification across users and clinics as well as a reduction in labour intensity, we have developed the Gavi system, which automates equilibration for vitrification using a novel closed system device.
Materials and Methods

Mouse embryos
Mouse F1 C57BL/6J x CBA embryos were supplied by Monash Animal Research Platform (Monash University, Melbourne, Australia), and were collected from superovulated females the morning after overnight matings and vitrified as zygotes (Day 1). Mouse Quackenbush Swiss embryos were supplied by CSIRO (Sydney, Australia) and were collected from superovulated females the morning after overnight matings then cultured in vitro in sequential embryo media until being vitrified as either 6 -8 cell cleavage stage embryos (Day 3), blastocysts (Day 5) or fully hatching blastocysts (Day 6). Animal experiments were approved by the Monash University Animal Ethics Committee (application MMCA 2012/04) or CSIRO Animal Ethics Committee (application 2010/09).
Human embryos
Human embryos were generated by ART as described previously (Roy et al., 2014) . The embryos were donated for research via an informed consent process and were vitrified blastocysts that the patients had deemed as excess to their reproductive needs. All relevant clinical procedures and research protocols were approved by Genea's human research Ethics Committee, an independent committee constituted according to the requirements of Australia's National Health and Medical Research Council (NHMRC), and the Embryo Research Licensing Committee of the NHMRC (license 309 718).
Culture media and vitrification solutions
Human embryos, both prior and subsequent to donation to research, were cultured in in-house manufactured sequential media identical in formulation to Sydney IVF embryo culture medium suite (Cook Medical). Mouse embryos were cultured in either this formulation (experiments with vitrified zygotes) or a new in-house manufactured sequential media suite (anticipated as commercially available from Genea Biomedx in 2015). All embryos were cultured under low (6%) oxygen in MINC benchtop incubators (Cook Medical).
Solutions for vitrification and warming were manufactured in-house in a HEPES buffered media containing 20 mg/ml human serum albumin and 0.01 mg/ml gentamicin identical in formulation to Cryobase (Cook Medical). Vitrification and warming solutions included: Vitrification Solution 1 containing 8% v/v ethylene glycol and 8% v/v DMSO; Vitrification Solution 2 containing 16% v/v ethylene glycol, 16% v/v DMSO and 0.68 mol/l trehalose; Warming Solution 1 containing 1 M trehalose; and Warming Solution 2 containing 0.5 M trehalose.
Description of the Gavi system
The Gavi system was developed at Genea (Sydney, Australia) and Planet Innovation (Melbourne, Australia) by teams of engineers, scientists and embryologists following a standard product development approach. The Gavi system performs automated equilibration for closed system vitrification of up to four embryos simultaneously. The system is comprised of: the instrument (Gavi) which performs fluid exchange using a robotic liquid handling unit with individual pipettes, has a heat sealing unit and includes the liquid nitrogen bucket; the single-use 'Pod' closed system device containing a novel microfluidic 'channel' that secures the embryo during fluid exchange (Supplementary data, Video S1) and vitrification; the 'Cassette' into which up to four Pods are loaded and which holds the Pods in liquid nitrogen storage; the 'Media Cartridge' containing Vitrification Solution 1 and Vitrification Solution 2; the 'Tip and Seal' consumable cartridge containing a pipette tip for fluid exchange and a lid to seal the Pod to prevent embryo or solution contact with liquid nitrogen; and the 'Tray' in which the Media Cartridge, Tip and Seal, and Cassette (containing Pods) are loaded (Supplementary data, Fig. S1 ).
Gavi system vitrification and warming
Vitrification using the 'Alpha' model Gavi system was performed on embryos using standardized procedures (Supplementary data, Video S2). Firstly, the instrument was turned on, the appropriate protocol was selected (zygote/ oocyte, cleavage stage embryo or blastocyst) and liquid nitrogen added to the liquid nitrogen bucket. The Media Cartridge and Tip and Seal were then placed into the Tray and loaded into the instrument. Next, Pods were placed into the Cassette, individual embryos were loaded into the Pods and the Cassette was loaded into Gavi. Media Cartridge caps and the cover of the Tip and Seal were removed and the program was started. On completion of the 13-to 18-min program (depending on the protocol) which includes automatic sealing of Pods, the Cassette was manually removed, dunked in liquid nitrogen with vertical stirring and then transferred to a standard liquid nitrogen dewar for storage.
For warming of embryos vitrified using the Gavi system, the cassette was held in or just above liquid nitrogen and a single pod was removed and dunked into a 378C water bath for 2 s with oscillation. The Pod seal was manually removed and 10 ml of room temperature Warming Solution 1 immediately added to the Pod. After 1 min, the embryo was transferred to a standard Nunc 4-well dish (Nunclon) containing 0.5 ml of Warming Solution 2 for 3 min, and then into 0.5 ml Cryobase for 5 min followed by fresh 0.5 ml Cryobase for 1 min. Embryos were then transferred to Genea Cleavage or Blastocyst Medium (depending on developmental stage) for further culture.
Cryotop vitrification and warming
Manual Cryotop (Kitazato, Japan) vitrification and warming of mouse and human embryos was performed essentially as described by Roy et al. (2014) . All solutions used were as per the Gavi system protocol and warmed to room temperature unless stated otherwise. In brief, embryos were incubated in Vitrification Solution 1 for up to 11 min for mouse embryos and up to 15 min for human embryos. After an initial shrinkage, embryos regained their original volume and were transferred into Vitrification Solution 2 for 1 -1.5 min. Embryos were then transferred onto the Cryotop strip in an extremely small volume (,0.1 ml) of solution which was then plunged into liquid nitrogen. After addition of the protective cover, the Cryotop was transferred to liquid nitrogen storage.
Warming of Cryotop vitrified embryos was performed by removal of the protective cover under liquid nitrogen and immersion of the strip in 2.5 ml of 378C Warming Solution 1 for 1 min. Embryos were then transferred to 0.5 ml of Warming Solution 2 for 3 min, and then into 0.5 ml Cryobase for 5 min followed by fresh 0.5 ml Cryobase for 1 min. Upon completion of the warming procedure, embryos were transferred to Genea Cleavage or Blastocyst Medium (depending on the developmental stage) for further culture.
Mouse embryo testing
Experiments with Quackenbush Swiss mouse embryos were performed at Genea while those with F1 C57BL/6J x CBA mouse embryos were performed at Planet Innovation on the same instrument model (Alpha prototype). On the day of vitrification, mouse embryos were divided equally based on embryo grade and developmental stage into three groups, those for Cryotop vitrification, those for Gavi system vitrification or a fresh group which did not undergo vitrification. Vitrification was subsequently performed in alternating groups of up to four embryos using Cryotop or Gavi system methodology. Vitrified embryos were warmed the following day in alternating Cryotop and Gavi groups, and then cultured in Cleavage Medium or Blastocyst Medium as appropriate, with the exception of vitrified-warmed fully hatched blastocysts which were cultured in dishes coated with collagen (Becton Dickinson; Cat # 354456) for assessment of embryo attachment and the outgrowth of embryonic cells. Experiments were repeated a minimum of four times with the exception of fully hatched blastocyst experiments which were repeated twice.
Human blastocyst testing
Experiments with human embryos were performed at Genea. The donated human embryos were received as vitrified blastocysts on Fibreplug (CryoLogic, Australia) or Cryotop carriers. These embryos were warmed with a protocol to match the vitrification procedure and then transferred to Blastocysts Medium. The human embryos were allowed to recover in culture for 4 -24 h depending on the day of vitrification and the developmental stage of the embryo. They were then assessed for developmental stage and grade (only grade I and II embryos were utilized) and allocated into either Gavi or Cryotop groups keeping the proportion of higher quality and/or developmentally advanced embryos equal between the groups. Embryos were then re-vitrified using either the Cryotop or Gavi system methodology and upon warming were cultured in Blastocyst Medium.
Vitrification-warming outcomes assessment
The outcomes measured to assess vitrification varied depending on embryonic stage at vitrification and embryo species. Recovery of vitrified embryos was defined as the presence of an embryo immediately upon warming. Survival was evaluated at the completion of the warming procedure and was defined as 75% or more cells intact within a human blastocyst and 100% of cells intact for mouse zygotes and cleavage stage embryos. Re-expansion was assessed 2 h after warming for human blastocysts and was considered to be successful if an embryo's cells occupied 90% or more of its original volume. Embryo cleavage was assessed for experiments using vitrifiedwarmed zygotes on Day 2 and was defined as an embryo containing two or more cells. All vitrified-warmed mouse embryos were assessed on Day 6 and Day 7 of in vitro development for embryo grade and developmental stage, with the exception of fully hatched blastocysts which were assessed for their ability to attach and outgrow on collagen culture dishes at Day 7 Semi-automated embryo vitrification and Day 8. Re-vitrified and warmed human blastocysts were assessed at 24 and 48 h after warming for embryo grade and developmental stage.
The percentage of embryos recovered was calculated as the number of embryos recovered per the total number of embryos vitrified. All other percentage calculations were based upon the number of embryos recovered, for example, the percentage of embryos survived was calculated as the number of survived embryos per the number of embryos recovered. The exception to this was the fresh group in which all percentage calculations were based upon the total number of embryos cultured in that group.
Measurement of cooling and warming rates
The Gavi Pod cooling rate was measured using a fine gauge type K thermocouple (RS 397-1589; RS Components, Australia) with a calibrated portable data acquisition module (DT 9806; Data Translation, Massachusetts, USA). The thermocouple probe was placed as close as possible to where the embryo would normally be loaded, 1 mL of Vitrification Solution 2 dispensed to cover the probe and the Pod heat sealed. Pods were then carefully loaded into cassettes and immersed in liquid nitrogen with vertical stirring. The Pod warming rate was measured as described for cooling with the exception that vitrified Pods were removed from cassettes under liquid nitrogen and individually submerged in a 378C water bath with oscillation. The cooling and warming rates were calculated as the rate (8C/minute) of cooling from 08C to 21338C and rate of warming from 21338C to 08C respectively. As a control for testing procedures, the cooling rate for the Rapid-i closed system vitrification device (Vitrolife) was also measured, the result being on average 12158C/min, a deviation of only 1758C/min from the reported claim by the manufacturer of 14008C/min.
Statistical analyses
Statistical analyses comparing mouse embryo vitrification outcomes between Gavi, Cryotop and fresh controls were conducted using Minitab 16 (Minitab, Inc.), with a P-value of ,0.05 considered statistically significant. Comparison of contingency tables was performed by Pearson's chi-squared test with the exception of analyses where an expected cell count was ,5, in which case Fisher's exact (two-tailed) test was performed.
Results
Mouse zygotes
The recovery of mouse zygotes vitrified after automated processing with the Gavi system was 97%, which was comparable to Cryotop controls (P ¼ 0.22) ( Table I ). In vivo embryo development was also equivalent, including identical development to fully hatched blastocysts with both Gavi and Cryotop groups being 43% by Day 6 and 57% by Day 7. However, further Gavi protocol optimization is required to improve zygote survival after vitrification-warming.
Mouse cleavage stage embryos
Cleavage stage mouse embryos (6-8 cell embryos) processed with the automated Gavi system achieved equivalent in vitro outcomes to that of the Cryotop method (Table II) . Recovery was 100% for both Gavi and Cryotop vitrified-warmed embryos, development to the blastocyst stage by Day 5 was 85% for Gavi and 92% for Cryotop controls (P ¼ 0.26), and development to fully hatched blastocysts by Day 6 was 38% for Gavi and 30% for Cryotop controls (P ¼ 0.33).
Mouse blastocysts
Mouse blastocysts processed with the automated Gavi system had an exceptionally high embryo recovery rate after vitrification-warming of 99%, which was identical to the Cryotop controls (Table III) . Development to fully hatched blastocysts by Day 6 and Day 7 was comparable between Gavi and Cryotop vitrified-warmed groups, being 41 and 45% (P ¼ 0.4), respectively, for Day 6, and 54 and 50% (P ¼ 0.46), respectively, for Day 7. Using this same protocol to process fully hatched blastocysts using the Gavi system resulted in equivalent embryo attachment to collagen coated dishes after vitrification-warming to that of Cryotop controls (Table IV) . Furthermore, the outgrowth of embryonic cells to collagen coated dishes at Day 8 was significantly higher for embryos vitrified-warmed using the Gavi system, being 70% as compared with 41% for Cryotop controls (P ¼ 0.02).
Human blastocysts
The recovery of human embryos after re-vitrification and warming was 100% for blastocysts processed with either the Gavi system or manual Cryotop method (Table V) . The proportion of cells which were considered to have survived after warming was 91% for Gavi vitrified-warmed embryos when compared with 77% for Cryotop controls. In line with this, there were more grade 1 and grade 2 fully hatched blastocysts 24 h after warming for Gavi processed embryos, being 17% for Gavi compared with 8% for Cryotop controls. This difference likely reflects low embryo numbers and was no longer apparent at 48 h post-warming.
Cooling and warming rates
The rate of cooling of the Gavi Pod (Fig. 1) , as calculated from 08C to 21338C, was determined to be 14 136 8C/min (Table VI) warming, as calculated from 21338C to 08C, was determined to be 11 2398C/min.
Discussion
Cryopreservation of embryos is an essential component of a successful ART clinic, with vitrification the method-of-choice due to excellent embryo survival and clinical outcomes (Loutradi et al., 2008; AbdelHafez et al., 2010; Roy et al., 2014) . However, vitrification is a labour-intensive and time-consuming task that involves embryologists physically moving the embryo from one solution to another. This makes it impossible to control and standardize the many vitrification variables such as actual temperatures, the exact duration of incubations and the diffusion gradients of solutions at the embryo level. As a result, the success of vitrification can be highly variable between embryologists and ART clinics (Gosden, 2011) . Demanding labour requirements and the recognized need for standardization inspired us to attempt to automate the vitrification process. Through extensive voice-of-customer studies, we determined that ART clinics had several key requirements for an automated vitrification instrument. Firstly, vitrification outcomes had to be comparable to an approved closed vitrification device or ideally to the gold standard Cryotop open manual system. Secondly, a closed system whereby the embryo was protected from contact with liquid nitrogen was required to prevent cross-contamination and to comply with increasingly stringent regulatory directives, for example in the European Union (European Union, 2004) . Additionally, the instrument had to be capable of vitrifying multiple embryos simultaneously. Furthermore, the process had to be 'low skill' and 'user friendly', allowing the embryologist to simply add the embryos to the instrument, press start and then return at the end of automatic equilibration for manual immersion of the carrier device into liquid nitrogen. Finally, the instrument had to be capable of successfully vitrifying embryos at different developmental stages including cleavage stage embryos and blastocysts.
Here we report the development of a vitrification instrument, Gavi, and its associated vitrification device, the Pod, which fulfils these voice-of-customer requirements. The Gavi system allows automated exchange of vitrification solutions for up to four embryos simultaneously, occurring in the Pod via a robotic liquid handling unit with individual pipettes and single-use pipette tips. Subsequently, the instrument seals each Pod with a lid to create a closed system to prevent embryo or solution contact with liquid nitrogen. At all stages of development, we benchmarked Gavi system vitrification outcomes to that of the manual Cryotop open system, which Genea ART clinics have used extensively to achieve excellent clinical results (Roy et al., 2014) . This study shows that the automated Gavi system can successfully equilibrate embryos at different developmental stages for vitrification, including mouse zygotes (Table I) , cleavage stage embryos (Table II) and blastocysts (including fully hatched blastocysts) (Tables III and IV) , as well as human blastocysts (Table V) . This includes an excellent embryo recovery rate of 99% (354/358) with the Gavi system. The development of the Gavi system to its current configuration involved 4 years of intensive research with close collaboration between teams of embryologists and engineers, two successive, improved main instrument prototypes (the Alpha model reported here and its predecessor concept demonstrator prototype) and 12 Pod revisions, over 30 protocol variations and 1250 vitrification runs. The Gavi system allows precise and reproducible control of all vitrification variables including temperature, time, volume, media concentration, fluidics speed and cooling rate, an impossible feat if performed manually. Embryo equilibration in the Pod by automated fluidics also results in reduced embryo handling therefore minimizing embryo stress and the potential for adverse events including embryo loss. Unlike manual vitrification, the only skill necessary to successfully operate the Gavi system is basic embryo handling, required for embryo loading into the Pod, and we have not observed operatordependent outcomes even with 'junior' technicians. Furthermore, valuable time for other work is gained by embryologists when embryos are vitrified using the Gavi system. We estimate 21 min of 'hands-on' time is required to vitrify four human blastocysts using Gavi, including paperwork and preparation for automated equilibration. This is compared with 57 min using Cryotop, including paperwork, preparation time, manual equilibration (each embryo processed 5 min apart with 15 min in Vitrification Solution 1 and 1.5 min in Vitrification Solution 2) and vitrification. One of the greatest challenges in the development of the Gavi system was how to hold the embryo in place during fluid exchange. The microfluidic dynamics of the Pod channel secures the embryo and prevents it from floating during automated fluid exchange (Supplementary data, Video S1) and as such may have applications beyond vitrification for automation of IVF procedures including general culture media changes. This patented approach (Henderson et al., 2011) is completely novel compared with those of other early stage projects which have attempted to automate vitrification using an enclosed microfluidics method (Swain et al., 2013) . Furthermore, the Gavi Pod has been specifically developed for heat sealing to allow for closed system vitrification, with its design limiting dissipation of heat from the seal location down to the bottom of the Pod where the embryo is located. As a result the sealing process does not affect vitrification outcomes as the temperature does not increase beyond physiological levels for the embryo if transferred to liquid nitrogen within the recommended time (unpublished data).
The success of the Gavi system in vitrifying-warming embryos, on par with that of the manual Cryotop method, challenges many of the preconceived fundamentals of vitrification. This includes the assumption that the ultra-fast speed of cooling and warming achieved with open vitrification devices is critical to cryopreservation success. We determined the Gavi Pod to have cooling rates in the order of 14 1008C/min and warming rates in the order of 11 2008C/min (Table VI) , which is much slower than those reported for Cryotop (Kuwayama et al., 2005b; Kuwayama, 2007) and is an unavoidable consequence of a closed system. Despite this, our data indicate that it is possible to achieve comparable in vitro cryopreservation outcomes to the Cryotop, which is supported by other studies which found equivalent clinical outcomes when comparing open and closed vitrification devices (Kuwayama et al., 2005a; Isachenko et al., 2007; Desai et al., 2013) . In fact, our cooling rate far exceeds that of other closed vitrification devices such as the Rapid-i and Vitrisafe, estimated to be 13008C/min (Vanderzwalmen et al., 2009; Desai et al., 2013) . This is because heat transfer to the embryo in the Pod occurs rapidly through plastic (with the embryo residing on the inner Pod surface with the outer surface in contact with liquid nitrogen) when compared with the Rapid-i and Vitrisafe where heat transfer occurs much more slowly through air (with the embryo residing on a plastic rod surrounded by air inside a separate straw with its outer surface in contact with liquid nitrogen).
Encouraged by the extremely promising vitrification results reported here for mouse and human embryos, we are now undertaking further research and development to ready the Gavi system for use in ART clinics. This includes verification and validation with successive models to the Alpha prototype including further extensive in vitro testing with mouse embryos from multiple strains as well as donated human blastocysts. Additionally, to satisfy regulatory requirements for medical devices, stability and toxicity testing of Gavi system consumables including Pods, premixed media and tips will be performed. If successful, clinical evaluation of pregnancy outcomes following transfer of human embryos vitrifiedwarmed using Gavi production units will commence in 2015. It is anticipated that the Gavi system will be initially released with protocols for human blastocysts, with future software updates to include oocyte, zygote and cleavage stage protocols.
In summary, we have developed an automated fluids exchange instrument and novel closed system device to allow rapid, efficient and reproducible vitrification of embryos for ARTs. using the Gavi system Alpha model are extremely promising, being comparable to that of manual Cryotop, and testing of advanced instrument models is currently underway. The success of the Gavi system demonstrates that it is possible to automate highly skilled and labour-intensive ART procedures and opens up the door for further innovations to standardize methodologies and improve patient outcomes.
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